Search | Clinical Trials Finder

Conditions: Atopic Dermatitis
Interventions: DSXS, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Rhinitis, Allergic, Perennial
Interventions: Fluticasone furoate nasal spray, Placebo nasal spray; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 8 Years
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 50
States / cities: Oxford, Alabama • Little Rock, Arkansas • Huntington Beach, California + 40 more

Conditions: Food Allergy
Interventions: Xolair, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 4 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Eosinophilic Esophagitis
Interventions: RPC4046, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 27
States / cities: Scottsdale, Arizona • Tucson, Arizona • Oceanside, California + 24 more

Conditions: Asthma
Interventions: Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Anaheim, California • Chula Vista, California • Fresno, California + 29 more

Conditions: Allergy
Interventions: ALK Ragweed Tablet; Biological
Lead sponsor: ALK-Abelló A/S; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Atopic Dermatitis, Plaque Psoriasis
Interventions: PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 23
States / cities: Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Azelastine hydrochloride and Fluticasone propionate, Dymista™, Placebo; Drug · Other
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 12 Years and older
Enrollment: 1,535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Down Syndrome, Edwards Syndrome, Patau Syndrome, Klinefelter Syndrome, Turner Syndrome, DiGeorge Syndrome, Chromosome Deletion, Aneuploidy
Interventions: Blood sampling for Laboratory Developed Test (LDT) analysis; Other
Lead sponsor: Progenity, Inc.; Industry
Eligibility: 18 Years to 54 Years · Female only
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 8
States / cities: Scottsdale, Arizona • Eunice, Louisiana • Brooklyn, New York + 5 more

Conditions: Atopic Dermatitis
Interventions: BxC-I17e (primed iMSC derived Extracellular vesicles(EV)), Placebo; Drug
Lead sponsor: Brexogen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: North Little Rock, Arkansas • Camp Hill, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Asthma in Children, Asthma Chronic
Interventions: Asthma Ctrl+, Control; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 18 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Aurora, Colorado • Cincinnati, Ohio

Conditions: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions: EDP-978, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity
Interventions: Bilastine, Placebo; Drug
Lead sponsor: Faes Farma, S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 13
States / cities: Oklahoma City, Oklahoma • Austin, Texas • Kerrville, Texas + 2 more

Conditions: Multiple Sclerosis, Optic Nerve, Neuritis
Interventions: Nerispirdine, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Allergic Conjunctivitis
Interventions: Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rhinitis, Allergic, Perennial and Seasonal
Interventions: FPNS, FPNS Placebo, Cetirizine, Cetirizine Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 31
States / cities: Little Rock, Arkansas • Denver, Colorado • Aventura, Florida + 27 more

Conditions: Grass Allergy, Rhinoconjunctivitis
Interventions: Not listed
Lead sponsor: Circassia Limited; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Normal, Illinois • Sylvania, Ohio + 2 more

Conditions: Asthma
Interventions: INTRAVENOUS GSK679586, INTRAVENOUS PLACEBO, FLUTICASONE PROPIONATE; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Medford, Oregon • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more

Conditions: Allergy, Peanut
Interventions: ligelizumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 55 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 29
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 23 more

Conditions: Allergic Conjunctivitis
Interventions: Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 7
States / cities: Phoenix, Arizona • Sacramento, California • Torrance, California + 3 more

Conditions: Asthma
Interventions: Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 122
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 119 more

Conditions: Atopic Dermatitis
Interventions: nemolizumab (CIM331), Placebo; Drug · Other
Lead sponsor: Chugai Pharmaceutical; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 18
States / cities: Anniston, Alabama • San Diego, California • Miami, Florida + 13 more

Conditions: Asthma
Interventions: Atuliflapon, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 64
States / cities: Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 52 more

Conditions: Asthma
Interventions: AZD7594; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 10
States / cities: Rolling Hills Estates, California • Miami, Florida • Miami Lakes, Florida + 7 more

Search by objective public record fields.

Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis

Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

Safety of ALK Ragweed Tablet

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

Expanded Noninvasive Genomic Medical Assessment: The Enigma Study

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Asthma Ctrl SMART Trial

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

Grass Observational Study

Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma